Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. · 2020
Read Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. by Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7169020.txt.
Introduction
Zhou and co-authors pool studies asking whether immune side effects predict benefit from checkpoint inhibitor cancer drugs, in BMC Medicine. These drugs can unleash immune attacks on healthy tissue, called immune-related adverse events. Some reports linked such events to better outcomes, but results conflicted.
Thirty studies with 4,971 patients entered the meta-analysis. Patients who developed immune side effects lived longer overall (hazard ratio 0.54) and stayed progression-free longer (hazard ratio 0.52) than those without. The pattern held across cancer types and drug classes, and for hormone-related and skin side effects and for low-grade events. The authors discuss whether the link reflects an immune system switched on strongly enough to hit both tumor and tissue.
Catalog record
| CREATOR | Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis By Xiaoxiang Zhou, Zhuoran Yao, Huaxia Yang, Naixin Liang, Xuan Zhang, Fengchun Zhang Published in: BMC Medicine DOI: 10.1186/s12916-020-01549-2 ABSTRACT Background A number of studies have reported an association between the occurrence of immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment with immune checkpoint inhibitors (ICIs), but the results remain controversial. Methods Under the guidance of a predefined protocol and Preferred Reporting Items for Systematic Reviews and Meta-analyses statement, this meta-analysis included cohort studies investigating the association of irAEs and efficacy of ICIs in patients with cancer. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). Subgroup analyses involving the cancer type, class of ICIs, combination therapy, sample size, model, landmark analysis, and approach used to extract the data were performed. Specific analyses of the type and grade of irAEs were also performed. Results This meta-analysis included 30 studies including 4971 individuals. Patients with cancer who developed irAEs experienced both an OS benefit and a PFS benefit from ICI therapy compared to patients who did not develop irAEs (OS: hazard ratio (HR), 0.54, 95% confidence interval (CI), 0.45–0.65; p < 0.001; PFS: HR, 0.52, 95% CI, 0.44–0.61, p < 0.001). Subgroup analyses of the study quality characteristics and cancer types recapitulated these findings. Specific analyses of endocrine irAEs (OS: HR, 0.52, 95% CI, 0.44–0.62, p < 0.001), dermatological irAEs (OS: HR, 0.45, 95% CI, 0.35–0.59, p < 0.001), and low-grade irAEs (OS: HR, 0.57, 95% CI, 0.43–0.75; p < 0.001) yielded similar results. The association between irAE development and a favorable benefit on survival was significant in patients with cancer who were undergoing treatment with programmed cell death-1 inhibitors (OS: HR, 0.51, 95% CI, 0.42–0.62; p < 0.001), but not cytotoxic T-lymphocyte antigen-4 inhibitors (OS: HR, 0.89, 95% CI, 0.49–1.61; p = 0.706). Additionally, the association was significant in patients with cancer who were treated with ICIs as a monotherapy (OS: HR, 0.53, 95% CI, 0.43–0.65; p < 0.001), but not as a combination therapy (OS: HR, 0.62, 95% CI, 0.36–1.05; p = 0.073). Conclusions The occurrence of irAEs was significantly associated with a better ICI efficacy in patients with cancer, particularly endocrine, dermatological, and low-grade irAEs. Further large-scale prospective studies are warranted to validate our findings. Systematic review registration PROSPERO CRD42019129310. BACKGROUND Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed cell death-1 (PD-1) pathways are reshaping the landscape of cancer therapy, yielding unprecedented clinical success in treating multiple cancer types [1]. By blocking the inhibitory pathway between T lymphocytes and tumor cells or antigen-presenting cells, ICIs aim to release the brake of the anergized T cells and reactivate their antitumor cytolytic function [2]. Monoclonal antibodies targeting CTLA-4 and PD-1/programmed cell death ligand-1 (PD-L1) axes are currently two major categories applied in cancer immunotherapies. Immune-related adverse events (irAEs) are a unique spectrum of side effects of ICIs that resemble autoimmune responses. irAEs affect almost every organ of the body and are most commonly observed in the skin, gastrointestinal tract, lung, and endocrine, musculoskeletal, and other systems [3]. Since irAEs occur via a process of immune activation, suggesting that the exhausted immune cells have been reinvigorated and attack not only tumor cells but also normal tissue, theoretically, the occurrence of irAEs may indicate a better response to ICI therapy. Nevertheless, whether irAE development is predictive of the ICI response remains controversial. A number of recent studies has supported this hypothesis by showing favorable outcomes for patients with non-small cell lung cancer (NSCLC) and melanoma who developed various irAEs in response to immune checkpoint inhibition [4–22]. However, a definite conclusion has not been drawn based on the findings from each single study, as contradictory results exist [23–35]. A systemic review included 16 studies and reported that irAEs such as pneumonitis, thyroid disorders, myalgias, and mucosal toxicity did not show a significant correlation with overall survival (OS) [36]. However, this review contained an insufficient number of studies and pooled analyses were not performed. Controversy persists regarding whether irAE development predicts the ICI response. A robust and precise systemic review is required to evaluate the association between irAE occurrence and the efficacy of ICIs. Herein, we conducted a systemic review of the published studies to investigate the association between irAE occurrence and the efficacy of ICIs. We used a standard meta-analysis approach to obtain a statistical and comprehensive view of the association. Our study addressed the question using the PECO tools: (P) patients with cancer receiving ICIs, (E) occurrence of irAEs, (C) non-occurrence of irAEs, (O) efficacy of ICIs (measured using different outcomes). To the best of our knowledge, the present study is the first meta-analysis to explore the association of the occurrence of irAE and the efficacy of ICIs by pooling the results of eligible studies collectively. Additionally, we separately pooled the predictive effects of different irAE types and irAE grades to investigate their specific roles in homogeneous settings. METHODS This systematic review and meta-analysis was conducted under the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [37]. We prospectively registered the protocol in PROSPERO (ID: CRD42019129310). Additional information about the methods is provided in the appendix (Additional file 1: Supplementary Methods). Literature search strategy We retrieved articles from the PubMed, Embase, and Cochrane databases to identify studies that reported the association between irAE occurrence and the efficacy of ICIs in patients with cancer that were published from database inception to March 22, 2019. The key retrieval items included irAEs, PD-1, PD-L1, CTLA-4, efficacy, and cancer. No restriction for time was established, while language was confined to English. We also manually reviewed the citations of relevant reviews, editorials, and commentaries and included relevant studies to avoid omission. We performed an additional retrieval from the database inception to June 3, 2019, to identify recent published studies using the same procedure. Inclusion and exclusion criteria The following inclusion criteria were adopted: Studies that enrolled patients diagnosed with cancer who had been treated with at least one of the following ICIs: nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, or ipilimumabStudies that reported an association between irAE occurrence and ICI efficacy in patients with cancer, including hazard ratios (HRs) of OS and progression-free survival (PFS) in patients who experienced irAEs versus non-irAE patientsStudies that reported available survival data for the extraction of HRs and 95% confidence intervals (CIs) or p valuesStudies that enrolled patients who had received prior treatment or current combination treatment were eligible (e.g., chemotherapy, radiotherapy, and vaccine therapy)Prospective or retrospective cohort studies, including on-trial and off-trial patientsStudies published in peer-reviewed journals in English. Studies not adhering to the inclusion criteria were excluded. Other exclusion criteria were as follows: Studies that reported adverse events that were not related to immune functionStudies that reported only survival curves and p values, but not HRs, for the association between the occurrence of irAEs and the efficacy of ICIsFor duplicate publications or overlapping study populations, we included only the most recent and complete report. Data collection and quality assessment Two researchers (X.Z. and Z.Y.) independently extracted data from the included publications in accordance